1. |
Pirker R, Minar W. Chemotherapy of advanced non-small cell lung cancer[J]. Front Radiat Ther Oncol, 2010, 42:157-163.
|
2. |
Kim YH, Kim JS, Choi YH, et al. Phase Ⅱ study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer[J]. Int J Clin Oncol, 2002, 7(2):114-119.
|
3. |
Ricciardi S, Tomao S, de Marinis F. Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer[J]. Ther Clin Risk Manag, 2009, 5:781-787.
|
4. |
Cohen MH, Cortazar P, Justice R, et al. Approval summary:pemetrexed maintenance therapy of advanced/metastatic nonsquamous, non-small cell lung cancer (NSCLC)[J]. Oncologist, 2010, 15(12):1352-1358.
|
5. |
Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST:evolving considerations for PET response criteria in solid tumors[J]. J Nucl Med, 2009, 50(Suppl 1):122S-150S.
|
6. |
孙燕, 周际昌. 临床肿瘤内科手册[M]. 4版. 北京:人民卫生出版社, 2003:97-107.
|
7. |
Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J]. N Engl J Med, 2002, 346(2):92-98.
|
8. |
Rollins KD, Lindley C. Pemetrexed:a multitargeted antifolate[J]. Clin Ther, 2005, 27(9):1343-1382.
|
9. |
Chattopadhyay S, Moran RG, Goldman ID. Pemetrexed:biochemical and cellular pharmacology, mechanisms, and clinical applications[J]. Mol Cancer Ther, 2007, 6(2):404-417.
|
10. |
张静, 范继业, 程艳坤, 等. 培美曲塞二钠的合成研究进展[J]. 河北化工, 2009, 32(5):5-6, 21.
|
11. |
Standfield L, Weston AR, Barraclough H, et al. Histology as a treatment effect modifier in advanced non-small cell lung cancer:a systematic review of the evidence[J]. Respirology, 2011, 16(8):1210-1220.
|
12. |
姜金, 李伦, 王晓晶, 等. 培美曲塞联合铂类对比吉西他滨联合铂类治疗晚期非小细胞肺癌的meta分析[J]. 中国肺癌杂志, 2011, 14(1):43-48.
|
13. |
Chen M, Shao W, He J, et al. Role of pemetrexed and platinums combination in patients with non-small cell lung cancer[J]. Curr Drug Targets, 2010, 11(1):29-36.
|
14. |
廖日强, 吴一龙. 培美曲塞在肺癌治疗中的新进展[J]. 中国处方药, 2010, 3(3):46-49.
|
15. |
Scagliotti GV, Parikh P, Von Pawel J, et al. PhaseⅢ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer[J]. J Clin Oncol, 2008, 26(21):3543-3551.
|
16. |
Omlin A, D'addario G, Gillessen S, et al. Activity of pemetrexed against brain metastases in a patient with adenocarcinoma of the lung[J]. Lung Cancer, 2009, 65(3):383-384.
|
17. |
Ongali B, Hellal F, Rodi D, et al. Autoradiographic analysis of mouse brain kinin B1 and B2 receptors after closed head trauma and ability of Anatibant mesylate to cross the blood-brain barrier[J]. J Neurotrauma, 2006, 23(5):696-707.
|
18. |
Dogan M, Yalcin B, Utkan G, et al. Activity of pemetrexed on brain metastases from non-small cell lung cancer:what is the mechanism?[J]. Lung Cancer, 2009, 66(3):399.
|